Biogen (NASDAQ:BIIB) Reaches New 12-Month High Following Earnings Beat

Biogen Inc. (NASDAQ:BIIB)’s stock price reached a new 52-week high on Friday following a stronger than expected earnings report. The stock traded as high as $195.96 and last traded at $194.6910, with a volume of 237889 shares traded. The stock had previously closed at $185.36.

The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.27. The firm had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a net margin of 15.98% and a return on equity of 14.13%. The business’s revenue for the quarter was down 7.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat on both EPS ($1.99 vs. consensus ~1.72) and revenue ($2.28B vs. ~$2.21B); investors reacted favorably to the upside. BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat ’26 EPS View
• Positive Sentiment: Biogen raised FY‑2026 adjusted EPS guidance to $15.25–$16.25, above consensus — a major driver of the rally as it signals stronger full‑year profitability expectations. Biogen forecasts annual profit above estimates as Leqembi sales pick up
• Positive Sentiment: Sales of Leqembi and newer launches (Skyclarys, Zurzuvae) showed meaningful growth and helped offset MS declines, supporting upside to future revenue mix and margins. Biogen Hits 52-Week High, Alzheimer’s Drug Sales Jump
• Positive Sentiment: Recent analyst support (RBC buy) and favorable coverage helped sentiment alongside the earnings/guidance beat. Biogen (BIIB) Receives a Buy from RBC Capital
• Neutral Sentiment: Management released the full earnings slide deck and call transcript — useful for modeling guidance assumptions and product-level trends but not market-moving on its own. Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Core MS franchise continued to decline, driving overall revenue down ~7.2% YoY; management said MS revenue pressures will persist, which limits near‑term top‑line growth. Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide
• Negative Sentiment: Some outlets note Biogen “swung to a loss” on certain GAAP measures and expect continued portfolio declines, underlining execution and pricing risks in legacy products. Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles

Analyst Ratings Changes

Several equities analysts have commented on BIIB shares. Truist Financial lifted their target price on shares of Biogen from $142.00 to $190.00 and gave the stock a “hold” rating in a research report on Thursday, January 8th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $225.00 price target on shares of Biogen in a research report on Thursday, January 8th. Sanford C. Bernstein set a $191.00 price objective on Biogen in a research report on Tuesday. Piper Sandler restated a “neutral” rating and issued a $157.00 price objective (up previously from $118.00) on shares of Biogen in a research note on Friday, November 21st. Finally, Mizuho raised their target price on Biogen from $177.00 to $207.00 and gave the company an “outperform” rating in a research report on Thursday, January 8th. Eleven analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $193.77.

Insider Activity

In related news, insider Priya Singhal sold 748 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $179.30, for a total transaction of $134,116.40. Following the sale, the insider owned 6,271 shares of the company’s stock, valued at approximately $1,124,390.30. This represents a 10.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.18% of the company’s stock.

Institutional Investors Weigh In On Biogen

A number of institutional investors and hedge funds have recently modified their holdings of BIIB. Vanguard Group Inc. lifted its stake in Biogen by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company’s stock worth $3,070,514,000 after purchasing an additional 157,857 shares in the last quarter. State Street Corp increased its holdings in shares of Biogen by 1.0% in the second quarter. State Street Corp now owns 7,468,807 shares of the biotechnology company’s stock worth $938,007,000 after purchasing an additional 71,897 shares during the period. Geode Capital Management LLC raised its position in shares of Biogen by 1.9% in the second quarter. Geode Capital Management LLC now owns 3,918,150 shares of the biotechnology company’s stock worth $490,089,000 after buying an additional 71,286 shares in the last quarter. Invesco Ltd. boosted its stake in Biogen by 4.2% during the third quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock valued at $338,731,000 after buying an additional 98,001 shares during the period. Finally, Norges Bank purchased a new position in Biogen during the second quarter worth about $284,358,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Price Performance

The business has a 50 day simple moving average of $176.94 and a two-hundred day simple moving average of $156.67. The firm has a market capitalization of $29.51 billion, a P/E ratio of 18.34, a price-to-earnings-growth ratio of 1.56 and a beta of 0.16. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.04 and a current ratio of 2.72.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.